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Metabolic Syndrome and the Risk of 
Ischemic Heart Disease and Stroke among 
Middle-Aged Japanese
Choy-Lye CHEI1), Kazumasa YAMAGISHI1), Takeshi TANIGAWA1),2), Akihiko KITAMURA3), 
Hironori IMANO3), Masahiko KIYAMA3), Shinichi SATO4), and Hiroyasu ISO5)
Limited information is available regarding risk of cardiovascular disease and trends for the metabolic syn-
drome in Asia. We examined the impact of the metabolic syndrome and its components on risk of cardio-
vascular disease among middle-aged Japanese according to four criteria. We followed 2,613 subjects from
a rural Japanese community who participated in cardiovascular health examinations between 1990 and
1993. After 27,477 person-years of follow-up through 2003, there were 42 incidents of ischemic heart dis-
ease, 73 total strokes (54 ischemic and 18 hemorrhagic), and 115 total cases of cardiovascular disease. The
metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment
Panel III (NCEP-ATPIII), American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI),
International Diabetes Federation (IDF), and Japanese criteria. The multivariable hazard ratios (95%CI) asso-
ciated with the metabolic syndrome based on NCEP-ATPIII criteria were 2.1 (1.1–4.0) for ischemic heart dis-
ease, 1.7 (1.0–2.7) for total stroke, 2.0 (1.2–3.5) for ischemic stroke, 1.1 (0.4–2.8) for hemorrhagic stroke, 2.0
(1.3–3.1) for ischemic cardiovascular disease, and 1.7 (1.2–2.5) for total cardiovascular disease. The popu-
lation-attributable fractions of the metabolic syndrome based on NCEP-ATPIII criteria were 26–27% for
ischemic heart disease and ischemic stroke and 20% for total cardiovascular disease. The metabolic syn-
drome based on AHA/NHLBI, IDF and Japanese criteria had weaker associations with risk of cardiovascular
disease, and the association with risk of ischemic heart disease was not statistically significant. The meta-
bolic syndrome based on NCEP-ATP III criteria predicted risks of ischemic heart disease, ischemic stroke
and total cardiovascular disease, whereas that based on three other criteria predicted them less effectively.
(Hypertens Res 2008; 31: 1887–1894)
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Introduction
The metabolic syndrome is associated with increased risks of
both type 2 diabetes and cardiovascular disease (1–8). The
criteria of metabolic syndrome defined by the Third Report of
the National Cholesterol Educational Program Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cho-
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lesterol in Adults (Adult Treatment Panel III; NCEP-ATP III)
(9) have been widely accepted. Recently, the American Heart
Association (AHA) and the National Heart, Lung, and Blood
Institute (NHLBI) provided new guidelines for the diagnosis
of the metabolic syndrome (10). The definition adopted by
both NCEP-ATP III and AHA/NHLBI was based on five
commonly measured clinical criteria whereas the criteria pro-
posed by the International Diabetes Federation (IDF) (11) and
the new Japanese definition (12) were based on a precondi-
tion for the presence of abdominal obesity.
A recent prospective study in Japan has shown that the
metabolic syndrome and its components, defined by modified
NCEP-ATP III criteria, were associated with an increased
risk of ischemic cardiovascular disease (13). Another Japa-
nese study of diabetic patients showed an increased risk of
cardiovascular disease associated with the metabolic syn-
drome based on NCEP-ATPIII but not IDF criteria (14, 15).
To our knowledge, there are no studies that have examined
whether the criteria of the metabolic syndrome can accurately
predict the risk of incident cardiovascular disease among the
general Japanese population. Limited prospective studies
have been undertaken in Asian populations (13, 16–18).
In the present study, we examined the association between
the metabolic syndrome and risks of ischemic heart disease
and stroke in Japanese men and women according to four dif-
ferent criteria of the metabolic syndrome.
Methods
Study Populations
The subjects were residents of Kyowa, a rural farming com-
munity in the Ibaraki Prefecture, mid-eastern Japan (census
population in 1990 of ages 40–69: n=6,520), where annual
cardiovascular health examinations have been conducted
since 1981 (19). Residents aged ≥40 years old were invited
annually by the municipal government to be assessed for sev-
eral cardiovascular risk factors as a part of community stroke
prevention program. Overall participation rates were approx-
imately 60–70% from 1990 to 2003.
In the present study, we included a total of 2,660 subjects
(998 men and 1,662 women) aged 40–69 who participated in
cardiovascular health examinations between 1990 and 1993
that included waist circumference measurements. After
exclusion of persons with a history of ischemic heart disease
(n=15) or stroke (n=32) at baseline, a total of 2,613 subjects
were followed-up through 2003 to examine the association
between the metabolic syndrome and risks of ischemic heart
disease and stroke. There were 17 individuals (0.7%) who
moved out of the community during the follow-up period,
according to municipal emigration office records. Forty-three
(1.6%) people died during the follow-up. These cases were
censored at the date of emigration or death, respectively. The
median follow-up period was 10.5 years.
The study was approved by the Medical Ethics Committee
of the University of Tsukuba.
Endpoint Determination
The follow-up was conducted by annual cardiovascular risk
surveys in order to obtain information about ischemic heart
disease and stroke incidents from the participants. For non-
participants, these endpoints were ascertained by mailed
questionnaire and by the use of death certificates. From death
certificates, cases with stroke as an underlying cause of death
(“International Classification of Diseases,” 9th ed., pp. 410–
414, 428, 429 and 430–438) were selected. We also used
national insurance claims, ambulance records, reports by
local physicians and public health nurses for case ascertain-
ment. To confirm the diagnosis, all living patients were tele-
phoned or visited to obtain their medical history and records.
For deaths, we obtained information from families and
reviewed medical records.
The criteria for ischemic heart disease were modified from
those of the WHO Expert Committee (20). Definite myocar-
dial infarctions were indicated by typical chest pain, lasting
for ≥30 min with the appearance of abnormal and persistent
Q or QS waves on the electrocardiogram, changes in cardiac
enzyme activity, or both. Probable myocardial infarctions
were indicated by typical chest pain for which the findings of
electrocardiogram or enzyme activity were not available.
Angina pectoris was defined as repeated episodes of chest
pain during effort, especially when walking, usually disap-
pearing rapidly after the cessation of effort or use of sublin-
gual nitroglycerin. Sudden cardiac death was defined as death
within 1 h of symptom onset, a witnessed cardiac arrest, or
abrupt collapse not preceded by more than 1 h of symptoms.
Ischemic heart disease included definite or probable myocar-
dial infarction, angina pectoris, and sudden cardiac death.
Stroke was defined as a focal neurological disorder with
rapid onset that persisted at least 24 h or until death. The
determination of incident stroke was based on clinical criteria
(21). Stroke events were further subclassified as subarachnoid
hemorrhage, intraparenchymal hemorrhage, ischemic stroke
(non-embolic or embolic), primarily based on CT and/or MRI
(22). Stroke cases without the imaging studies were subclas-
sified according the clinical criteria (21) as subarachnoid
hemorrhage, intraparenchymal hemorrhage, ischemic stroke,
or stroke of undetermined type. The proportion of stroke
cases confirmed by CT or MRI was 92% for total stroke,
100% for subarachnoid hemorrhage, 86% for intraparenchy-
mal hemorrhage, and 94% for ischemic stroke.
A panel of three or four physician-epidemiologists made
the final diagnosis of ischemic heart disease and stroke,
blinded to the data of risk factor surveys.
Measurements
Height in stocking feet and weight in light clothing were mea-
sured. Body mass index was calculated as weight (kg) divided
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by square of height (m2). Well-trained observers measured the
waist circumference of the subjects at the level of the umbili-
cus to the nearest 1 cm while subjects were standing and
breathing normally. Blood pressure was measured by well-
trained technicians using mercury sphygmomanometers on
the right arm of seated participants after at least 5 min of rest.
Blood was drawn from seated participants into a plain, sili-
conized glass tube, and serum was separated. Serum glucose
was measured by the hexokinase method. Fasting was not
required. The distribution of time since the last meal was <2
h (40%), 2 h (35%), 3–7 h (19%) and ≥8 h (6%).
An interview was conducted to ascertain daily alcohol
intake, number of cigarettes smoked per day, use of medica-
tion for diabetes mellitus and hypertension, and past history
of stroke and ischemic heart disease. Persons who smoked at
least 1 cigarette/d were defined as current smokers, and those
who had not smoked for ≥3 months were defined as former
smokers.
Serum total cholesterol and high-density lipoprotein
(HDL)-cholesterol after heparin-manganese precipitation
were measured by the Liebermann-Burchard direct method
using the Autoanalyzer II (Technicon, Tarrytown, USA) at
the Osaka Medical Center for Health Science and Promotion.
The laboratory has been standardized under the CDC-NHLBI
Lipid Standardization Program, Centers for Disease Control
and Prevention, Atlanta, and successfully met the criteria for
precision and accuracy of triglyceride and total and HDL-
cholesterol measurements as an international member of the
US National Cholesterol Reference Method Laboratory Net-
work (CRMLN) (23).
Definition of the Metabolic Syndrome
According to the modified NCEP-ATPIII definition (9), sub-
jects who had three or more of the following criteria were
identified as having the metabolic syndrome: 1) triglycerides
≥1.69 mmol/L (≥150 mg/dL), 2) HDL cholesterol <1.03
mmol/L (<40 mg/dL) for men and <1.29 mmol/L (<50 mg/
dL) for women, 3) blood pressure ≥130/85 mmHg, or use of
antihypertensives, 4) fasting glucose ≥6.11 mmol/L (≥110
mg/dL) or non-fasting glucose ≥7.77 mmol/L (≥140 mg/dL),
or on treatment, or 5) abdominal obesity—modified waist cir-
cumference cutoffs (≥90 cm for men and ≥80 cm for women)
were used (24) instead of the waist circumference cutoffs
(>102 cm for men and >88 cm for women) proposed in the
existing NCEP-ATPIII criteria.
According to the AHA/NHLBI definition (10), the meta-
bolic syndrome was defined as the presence of three or more
of the following: 1) elevated triglyceride level ≥1.69 mmol/L
(≥150 mg/dL) or on treatment, 2) reduced HDL-cholesterol
<1.03 mmol/L (<40 mg/dL) for men and <1.29 mmol/L
(<50 mg/dL) for women, or on treatment, 3) elevated blood
pressure ≥130/85 mmHg, or use of antihypertensive medica-
tion, 4) elevated fasting glucose ≥5.56 mmol/L (≥100 mg/
dL) or non-fasting glucose ≥7.22 mmol/L (≥130 mg/dL), or
on treatment, or 5) abdominal obesity, waist circumference
≥90 cm for men and ≥80 cm for women.
According to the new IDF definition (11) (the IDF consen-
sus worldwide definition of the metabolic syndrome [article
online]: available from http://www.idf.org/webdata/docs/
IDF_Meta_def_final.pdf/), Japanese people were defined as
having the metabolic syndrome if the subjects had abdominal
obesity (waist circumference cutoffs ≥90 cm for men and
≥80 cm for women) plus two or more of the following risk
factors: 1) elevated triglyceride level ≥1.69 mmol/L (≥150
mg/dL) or on treatment, 2) low HDL cholesterol <1.03
mmol/L (<40 mg/dL) for men and <1.29 mmol/L (<50 mg/
dL) for women or on treatment, 3) high blood pressure ≥130/
85 mmHg or use of antihypertensives, or 4) high fasting glu-
cose ≥5.56 mmol/L (≥100 mg/dL) or non-fasting glucose
≥7.22 mmol/L (≥130 mg/dL) or on treatment.
According to the Japanese definition (12), the metabolic
syndrome was identified if subjects had abdominal obesity
(waist circumference ≥85 cm for men and ≥90 cm for
women), in addition to two or more of the following criteria:
1) triglyceride level ≥1.69 mmol/L (≥150 mg/dL) or on treat-
ment, 2) HDL cholesterol <1.03 mmol/L (<40 mg/dL) or on
treatment, 3) blood pressure ≥130/85 mmHg or use of anti-
hypertensive medication, or 4) fasting glucose ≥6.11 mmol/L
(≥110 mg/dL) or non-fasting glucose ≥7.77 mmol/L (≥140
mg/dL) or on treatment.
Statistical Analysis
Age-adjusted mean values or the prevalence of metabolic
syndrome, its components and other cardiovascular risk fac-
tors were compared between incident cases of ischemic heart
disease and stroke and non-cases using the analysis of covari-
ance or χ 2 tests.
Person-years were calculated as the sum of individual fol-
low-up time until the occurrence of incident ischemic heart
disease, stroke, death, emigration, or until the end of 2003.
The hazard ratios of ischemic heart disease and stroke and the
respective 95% confidence intervals (CI) were calculated
with reference to the risk of individuals without the metabolic
syndrome using the Cox proportional hazards model. The
results were adjusted for age (years), and other potential con-
founding variables such as smoking status (never, former, and
current smokers), alcohol intake category (never, former, and
current <46, 46–68 and ≥69 g/d ethanol), time since last meal
(<2, 2, 3–7, and ≥8 h), and total serum cholesterol levels
(mmol/L). The proportional hazards assumption was tested
using an interaction terms of time by metabolic syndrome and
was not violated for each analysis. We also calculated the
population attributable fraction (PAF) to examine the contri-
bution of the metabolic syndrome to risk of cardiovascular
disease using multivariable hazard ratios of statistical signifi-
cance and the proportions of cases in each categories (25).
PAF was estimated as Pd × (HR − 1)/HR, where Pd is the pro-
portion of cases falling into the metabolic syndrome category
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Table 1. Sex-Specific Baseline Characteristics of Cardiovascular Disease Cases and Non-Cases among Japanese Aged 40–69
Years
Ischemic 
heart disease
Total 
stroke
Ischemic 
stroke
Hemorrhagic 
stroke
Ischemic 
cardiovascular 
disease
Total 
cardiovascular 
disease
Non-cases
Men
n 28 31 26 5 52 60 908
Age, years 59.5±2* 60.2±2† 60.0±2* 61.6±4 59.6±1* 59.9±1‡ 55.6±0.3
Systolic blood pressure, mmHg 138±3 146±3‡ 147±3‡ 139±7 141±2‡ 141±2‡ 134±0.5
Diastolic blood pressure, mmHg 82±2 84±2* 84±2 85±5 83±2* 83±1 80±0.3
Use of antihypertensive medication, % 32* 18 19 14 25 23 17
High blood pressure, % 47† 34 34 34 39* 36* 24
Body mass index, kg/m2 23.5±0.5 23.6±0.5 23.8±0.5 22.6±1.3 23.7±0.4 23.5±0.4 23.7±0.1
Waist circumference, cm 82.9±1.5 84.0±1.4 85.1±1.6 78.3±3.5 84.4±1.1 83.5±1.0 84.0±0.3
Waist circumference (≥85 cm), % 42 50 53 38 49 46 49
Waist circumference (≥90 cm), % 24 41* 41 38 34 32 24
Serum total cholesterol, mmol/L 5.13±0.16 4.87±0.16 4.97±0.17 4.35±0.39 5.06±0.12 5.00±0.11 4.96±0.03
Hypercholesterolemia, % 15 14 17 2 16 16 20
Serum triglycerides, mmol/L 2.13±0.21 1.82±0.20 1.96±0.21 1.13±0.49 2.07±0.15 1.95±0.14 1.79±0.04
Hypertriglyceridemia, % 49 40 47 1 50 43 42
Serum HDL-cholesterol, mmol/L 1.25±0.07 1.36±0.06 1.33±0.07 1.49±0.16 1.29±0.05 1.33±0.05 1.33±0.01
Low HDL-cholesterol, % 10 16 19 1 15 13 19
Serum glucose, mmol/L 8.16±0.45* 8.90±0.41‡ 9.09±0.44‡ 7.79±0.99 8.61±0.33‡ 8.46±0.31‡ 7.02±0.08
Glucose abnormality, % (≥6.11mmol/L) 6 28‡ 30‡ 19 18‡ 17† 7
Current smokers, % 59 66 67 62 61 61 53
Ethanol intake, g/d 28.0±4.6 25.4±4.3 26.9±4.7 17.1±10.8 27.8±3.4 27.1±3.1 22.9±0.8
Women
n 14 42 28 13 40 55 1,590
Age, years 65.6±2‡ 62.9±1‡ 63.0±2‡ 62.2±2† 63.9±1‡ 63.6±1‡ 54.8±0.2
Systolic blood pressure, mmHg 130±4 136±3* 135±3 139±4* 133±3 134±2 130±0.4
Diastolic blood pressure, mmHg 75±3 79±2 77±2 83±3* 77±2 78±1 77±0.3
Use of antihypertensive medication, % 21 30 35 21 31* 28 19
High blood pressure, % 35 34 39 28 38* 35 24
Body mass index, kg/m2 24.4±0.8 25.5±0.5‡ 25.7±0.6† 25.4±0.9 25.3±0.5† 25.3±0.4‡ 23.8±0.1
Waist circumference, cm 84.4±2.5 84.1±1.4* 84.7±1.7* 82.9±2.6 84.6±1.5* 84.0±1.3* 81.0±0.2
Waist circumference (≥90 cm), % 41* 27 29 25 33* 29* 18
Waist circumference (≥80 cm), % 64 56 34 36 65 59 55
Serum total cholesterol, mmol/L 5.41±0.25 5.07±0.15 5.02±0.18 5.15±0.26 5.18±0.15 5.19±0.13 5.26±0.02
Hypercholesterolemia, % 34 22 22 24 27 27 31
Serum triglycerides, mmol/L 1.52±0.23 1.47±0.13 1.49±0.16 1.46±0.24 1.49±0.14 1.48±0.12 1.47±0.02
Hypertriglyceridemia, % 40 43* 46* 40 42 41* 29
Serum HDL-cholesterol, mmol/L 1.32±0.09 1.40±0.05 1.40±0.06 1.40±0.09 1.38±0.05 1.39±0.05 1.46±0.01
Low HDL-cholesterol, % 61* 41 44 36 50* 45* 32
Serum glucose, mmol/L 7.11±0.50 6.96±0.29 7.12±0.36 6.42±0.52 6.90±0.30 6.83±0.26 6.42±0.05
Glucose abnormality, % (≥6.11 mmol/L) 12 15‡ 16† 7 13† 13‡ 4
Current smokers, % 8 8 8 9 9 8 5
Ethanol intake, g/d 0.4±1.4 2.2±0.8 2.5±1.0 1.8±1.5 1.9±0.9 1.8±0.7 1.1±0.1
Values are mean±SEM, or proportions, adjusted for age. Serum triglycerides and glucose values were also adjusted for time since last
meal. Test for significance from non-cases: *p<0.05, †p<0.01, ‡p<0.001. HDL, high-density lipoprotein.
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and HR is hazard ratio in that category. The Greenland for-
mula was used to calculate 95% CI (26).
SAS statistical software (version 9.13; SAS Institute Inc.,
Cary, USA) was used for the analyses, and p<0.05 was
regarded as statistically significant
Results
After 27,477 person-years of follow-up, we documented 42
incident cases of ischemic heart disease (1.5 per 1,000 per-
son-years), 73 incident cases of total stroke (2.7 per 1,000
person-years), 54 incident cases of ischemic stroke (2.0 per
1,000 person-years), 18 incident cases of hemorrhagic stroke
(0.7 per 1,000 person-years), 92 incident cases of ischemic
cardiovascular disease (3.4 per 1,000 person-years), and 115
incident cases of total cardiovascular disease (4.2 per 1,000
person-years).
Table 1 compares age-adjusted values and proportions of
components of the metabolic syndrome and other cardiovas-
cular risk factors between incident cases and non-cases of car-
diovascular disease. Compared with non-cases, cases with
ischemic heart disease were older, more hypertensive,
smoked more, and had higher mean serum total cholesterol,
serum triglycerides, and serum glucose levels, and lower
mean HDL-cholesterol levels among both men and women.
Compared with non-cases, individuals who suffered from
ischemic stroke were older, more hypertensive, smoked more,
and had higher mean serum triglycerides and serum glucose
Table 2. Hazard Ratios (HR), Population Attributable Fraction (PAF), and 95% Confidence Interval (CI) of Cardiovascular
Disease Associated with the Metabolic Syndrome in Japanese Aged 40–69 Years
Metabolic syndrome
NCEP-ATP III criteria AHA/NHLBI criteria IDF criteria Japanese criteria
No Yes No Yes No Yes No Yes
No. at risk 1,808 805 1,750 863 1,919 694 2,174 439
Person-years 18,999 8,478 18,373 9,104 20,142 7,336 22,838 4,639
Ischemic heart disease
No. of cases 20 22 20 22 25 17 30 12
Age-adjusted HR (95% CI) 1.0 1.9 (1.1–3.6)* 1.0 1.7 (0.9–3.2) 1.0 1.4 (0.8–2.7) 1.0 1.6 (0.8–3.1)
Multivariable HR (95% CI) 1.0 2.1 (1.1–4.0)* 1.0 1.9 (1.0–3.5) 1.0 1.8 (0.9–3.4) 1.0 1.1 (0.5–2.2)
PAF (95% CI), % 27 (−0.5–48) — — —
Total stroke
No. of cases 38 35 37 36 43 30 50 23
Age-adjusted HR (95% CI) 1.0 1.6 (1.0–2.6)* 1.0 1.5 (1.0–2.4) 1.0 1.5 (0.9–2.4) 1.0 1.9 (1.1–3.1)*
Multivariable HR (95% CI) 1.0 1.7 (1.0–2.7)* 1.0 1.6 (1.0–2.5) 1.0 1.6 (1.0–2.7) 1.0 1.8 (1.1–3.1)*
PAF (95% CI), % 19 (−1–35) — — 14.0
Ischemic stroke
No. of cases 26 28 26 28 29 25 35 19
Age-adjusted HR (95% CI) 1.0 1.9 (1.1–3.3)* 1.0 1.7 (1.0–2.9) 1.0 1.9 (1.1–3.2)* 1.0 2.2 (1.3–3.9)†
Multivariable HR (95% CI) 1.0 2.0 (1.2–3.5)* 1.0 1.8 (1.0–3.1)* 1.0 2.2 (1.2–3.9)† 1.0 2.0 (1.1–3.6)*
PAF (95% CI), % 26 (2–44) 23 (−3–42) 25 (4–42) 18 (−0.6–33)
Hemorrhagic stroke
No. of cases 11 7 10 8 13 5 14 4
Age-adjusted HR (95% CI) 1.0 1.1 (0.4–2.9) 1.0 1.2 (0.5–3.2) 1.0 0.8 (0.3–2.3) 1.0 1.2 (0.4–3.5)
Multivariable HR (95% CI) 1.0 1.1 (0.4–2.8) 1.0 1.2 (0.5–3.2) 1.0 0.7 (0.3–2.2) 1.0 1.4 (0.5–4.6)
PAF (95% CI), % — — — —
Ischemic cardiovascular disease
No. of cases 44 48 44 48 51 41 62 30
Age-adjusted HR (95% CI) 1.0 1.9 (1.3–2.9)† 1.0 1.7 (1.1–2.6)* 1.0 1.7 (1.1–2.6)* 1.0 2.0 (1.3–3.0)†
Multivariable HR (95% CI) 1.0 2.0 (1.3–3.1)† 1.0 1.8 (1.2–2.7)† 1.0 2.0 (1.3–3.2)† 1.0 1.5 (1.0–2.4)
PAF (95% CI), % 26 (8–41) 23 (4–38) 23 (7–36) —
Total cardiovascular disease
No. of cases 59 56 58 57 68 47 81 34
Age-adjusted HR (95% CI) 1.0 1.7 (1.2–2.4)† 1.0 1.5 (1.1–2.2)* 1.0 1.5 (1.0–2.1)* 1.0 1.7 (1.1–2.5)*
Multivariable HR (95% CI) 1.0 1.7 (1.2–2.5)† 1.0 1.6 (1.1–2.3)* 1.0 1.6 (1.1–2.4)* 1.0 1.4 (0.9–2.1)
PAF (95% CI), % 20 (4–33) 18 (1–31) 16 (2–28) —
*p<0.05, †p<0.01. Multivariable HR adjusted for age, time since last meal, cigarette smoking, alcohol intake and serum total choles-
terol.
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levels among both men and women.
The hazard ratios of the metabolic syndrome and cardiovas-
cular disease are shown in Table 2. The metabolic syndrome
based on NCEP-ATP III criteria was significantly associated
with risks of ischemic heart disease, total stroke, ischemic
stroke, ischemic cardiovascular disease, and total cardiovas-
cular disease but was not associated with hemorrhagic stroke.
The respective multivariable hazard ratio (95% CI) associated
with the metabolic syndrome was 2.1 (1.1–4.0), 1.7 (1.0–2.7),
2.0 (1.2–3.5), 2.0 (1.3–3.1), 1.7 (1.2–2.5) and 1.1 (0.4–2.8).
Based on AHA/NHLBI and IDF criteria, we found similar or
weaker associations with risks of ischemic stroke, ischemic
cardiovascular disease, and total cardiovascular disease, and
no significant association with total stroke, hemorrhagic
stroke or ischemic heart disease. Using the Japanese criteria,
the metabolic syndrome was only significantly associated
with risks of total and ischemic strokes; the multivariable haz-
ard ratio (95% CI) was 1.8 (1.1–3.1) and 2.0 (1.1–3.6),
respectively.
The PAFs of ischemic heart disease, total stroke, ischemic
stroke, ischemic cardiovascular disease, and total cardiovas-
cular disease were between 19% and 27% for the metabolic
syndrome based on NCEP-ATP III criteria. The respective
PAFs were between 18% and 23% based on AHA/NHLBI
criteria and between 16% and 25% based on IDF criteria. The
PAFs of total and ischemic strokes for the metabolic syn-
drome were between 14% and 18% based on Japanese crite-
ria.
We also analyzed associations of the metabolic syndrome
components based on the four criteria and risks of ischemic
cardiovascular disease, stratified by the presence of abdomi-
nal obesity (Table 3). The multivariate hazard ratio of
ischemic cardiovascular disease according to NCEP-ATP III
criteria was 3.3 (1.0–11.2) in non-abdominal obese persons
with at least two risk factors and 5.1 (1.6–16.9) in abdominal
obese persons with at least two risk factors. The respective
hazard ratios were 4.3 (1.0–18.3) and 6.5 (1.6–27.5), accord-
ing to AHA/NHLBI and IDF criteria, and 3.4 (1.3–8.9) and
3.4 (1.3–9.0), according to the Japanese criteria.
Discussion
The metabolic syndrome based on NCEP-ATP III criteria was
associated with 2-fold increased risks of ischemic heart dis-
ease, ischemic stroke, and total cardiovascular disease,
whereas the metabolic syndrome based on AHA/NHLBI,
IDF, and Japanese criteria had weaker associations with risk
of cardiovascular disease, and the association with risk of
ischemic heart disease was not statistically significant. The
population attributable fraction of ischemic stroke was lower
for the metabolic syndrome based on Japanese criteria than
for that based on other criteria. Our results were consistent
Table 3. Multivariable Hazard Ratios of Ischemic Cardiovascular Disease According to the Number of Components of the Met-
abolic Syndrome, Stratified by the Presence of Abdominal Obesity
Metabolic syndrome
Abdominal obesity (−) Abdominal obesity (+)
No. of components except 
abdominal obesity
No. of components except 
abdominal obesity
0 1 2+ 0 1 2+
NCEP-ATP III criteria
No. at risk 415 560 495 126 355 662
Person-years 4,392 5,801 5,145 1,354 3,785 7,001
Ischemic cardiovascular disease
No. of cases 3 16 24 2 6 41
Multivariable HR (95% CI) 1.0 2.4 (0.7–8.4) 3.3 (1.0–11.2) 2.0 (0.3–11.9) 1.6 (0.4–6.6) 5.1 (1.6–16.9)†
AHA/NHLBI and IDF criteria
No. at risk 378 552 540 113 336 694
Person-years 3,996 5,719 5,623 1,221 3,583 7,336
Ischemic cardiovascular disease
No. of cases 2 16 25 1 7 41
Multivariable HR (95% CI) 1.0 3.4 (0.8–14.8) 4.3 (1.0–18.3)* 1.5 (0.1–16.3) 2.8 (0.6–13.7) 6.5 (1.6–27.5)*
Japanese criteria
No. at risk 567 767 499 67 274 439
Person-years 5,948 8,079 5,255 725 2,830 4,639
Ischemic cardiovascular disease
No. of cases 5 17 28 2 10 30
Multivariable HR (95% CI) 1.0 1.6 (0.6–4.5) 3.4 (1.3–8.9)* 2.4 (0.5–12.2) 2.2 (0.7–6.6) 3.4 (1.3–9.0)*
*p<0.05, †p<0.01. Multivariable HR adjusted for age, time since last meal, cigarette smoking, alcohol intake and serum total choles-
terol. HR, hazard ratio; CI, confidence interval.
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with those of other prospective studies that showed that the
metabolic syndrome based on NCEP-ATP III criteria was
associated with risks of mortality and incidence of cardiovas-
cular disease (1, 2, 4–7, 13, 16–18, 27, 28), and that the meta-
bolic syndrome based on IDF criteria was less predictive of
cardiovascular disease risk (29–31). The metabolic syndrome
based on NCEP-ATP III, but not IDF criteria, was associated
with cardiovascular disease among male diabetic patients (14,
15).
Based on the Japanese criteria, the excess risk of ischemic
cardiovascular disease was similar in non-abdominal obese
persons with at least two metabolic risk factors and abdomi-
nal obese persons with at least two risk factors. The lack of
significant associations of ischemic heart disease and
ischemic cardiovascular disease based on the Japanese crite-
ria was due to the inclusion of a high-risk group of persons
without abdominal obesity as a reference group. In other
words, excess risk of ischemic cardiovascular disease was
similar for persons with at least two metabolic risk factors,
irrespective of the presence of abdominal obesity. It is contro-
versial whether the abdominal obesity defined by waist cir-
cumference should be required for diagnosis of the metabolic
syndrome (27, 30). Waist circumference is a valuable compo-
nent of metabolic syndrome, but the requirement of an
increased waist circumference may lead to reduced predictive
power for cardiovascular disease (27, 29–33).
The strengths of the present study include the use of stan-
dardized measurements of waist circumference, serum lipids,
and blood pressure levels. The stroke surveillance was almost
complete, and a high percentages of the events were con-
firmed using imaging studies (92%).
The limitations of the present study were, first, the small
number of incident cases, particularly for ischemic heart dis-
ease. However, we found a statistically significant association
between the metabolic syndrome and risks of ischemic heart
disease and ischemic stroke. Second, we collected non-fast-
ing blood samples from 94% of the participants during the
1990–1993 examinations. We used non-fasting data at the
baseline examination, in particular, non-fasting serum triglyc-
erides ≥1.69 mmol/L (≥150 mg/dL) as a component of meta-
bolic syndrome. Although the justification of the use for the
same cutoff point as fasting status is under debate, the data of
non-fasting triglycerides can be used because of their signifi-
cant predictive power for ischemic heart disease (34). We
used non-fasting glucose ≥7.77 mmol/L as a component of
metabolic syndrome, and we may have misclassified partici-
pants with high blood glucose. However, we found no signif-
icant difference in the percentage of participants with high
blood glucose in non-fasting and fasting blood samples prob-
ably because we used the different cutoff points: ≥110 mg/dL
for fasting and ≥140 mg/dL for non-fasting. In men, the per-
centage of high blood glucose was 26% for non-fasting blood
samples and 30% for fasting blood samples. In women, the
respective percentages were 17% and 14%.
In summary, the metabolic syndrome based on NCEP-
ATPIII criteria predicted risks of ischemic heart disease,
ischemic stroke and total cardiovascular disease, whereas that
based on the other three criteria predicted them to a lesser
extent.
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